Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Brief Psych Intervention Reduced Distress Related to Advanced Cancer

June 3, 2017
By Leah Lawrence
Article
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

A brief psychological intervention-Managing Cancer and Living Meaningfully (CALM)-significantly reduced distress in patients with advanced cancer.

CHICAGO-A brief psychological intervention-Managing Cancer and Living Meaningfully (CALM)-significantly reduced distress in patients with advanced cancer, according to the results of a study (abstract LBA10001) presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6.

At 3 months post-intervention, more than half of patients had a clinically significant reduction in depressive symptoms.

“CALM appears to be an effective intervention that alleviates distress in individuals with advanced or metastatic cancer and helps them to manage the profound and practical problems that they face,” said Gary Rodin, MD, head of the department of supportive care at the Princess Margaret Cancer Centre in Toronto.

According to Rodin, advanced cancer triggers enormous distress and brings challenges that can seem overwhelming. Despite that, “there hasn’t been a routine or systematic approach to help people with these problems,” Rodin noted.

Rodin and colleagues developed CALM as a novel, brief, manualized psychotherapeutic intervention designed to alleviate distress and facilitate adjustment in this patient population. In this study, 305 patients with advanced cancer were randomly assigned to usual care with or without CALM.

Patients assigned to CALM participated in 3 to 6 individual 45- to 60-minute sessions delivered by trained healthcare professionals over 3 to 6 months. CALM focused on symptom management and communication with healthcare providers; changes in self and relations with close others; sense of meaning and purpose; and the future and mortality. Family members and caregivers were invited to attend.

At baseline, 3 months, and 6 months, participants were assessed for depressive symptoms, death-related distress, and other secondary outcomes. The primary outcome was change in depressive symptoms.

Compared with usual care, patients assigned to CALM reported less severe depressive symptoms at 3 months, and the difference at 6 months was even greater. At 3 months, there was a clinically meaningful reduction in depressive symptoms in 52% of patients assigned to CALM compared with 33% assigned to usual care; at 6 months the reduction was 65% with CALM and 35% with usual care.

In addition, participation in CALM helped prevent depression in patients who did not have depressive symptoms at study entry. At 3 months, only 13% of patients who received CALM developed depressive symptoms compared with 30% of patients who received usual care.

According to Rodin, there is great generalizability to the CALM intervention. “We have trained people in more than 20 countries and are now in the process of establishing a global network to train health professionals in delivering CALM and evaluating its effectiveness and feasibility,” he said.

Commenting on the study, ASCO Expert Don S. Dizon, MD, FACP, said, “Just like we have embraced the concept that palliative care is important along the cancer care continuum, and particularly for patients living with disease that is not curable, these data add much more to the important concept of paying attention to patients’ symptoms beyond cancer-specific outcomes. We can do things to improve their quality of life. Patients facing advanced disease still need our help.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Related Content

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Defining the Role of Immune Therapy in Multiple Myeloma

Roman Fabbricatore
August 16th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 16th 2025
Podcast

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 16th 2025
Article

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 16th 2025
Podcast

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 16th 2025
Article

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Russ Conroy
August 16th 2025
Article
Related Content

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Defining the Role of Immune Therapy in Multiple Myeloma

Roman Fabbricatore
August 16th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 16th 2025
Podcast

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 16th 2025
Article

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 16th 2025
Podcast

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 16th 2025
Article

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Russ Conroy
August 16th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.